share_log

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K：重大事件
美股sec公告 ·  05/06 12:59
Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the symbol VVOS, has reported on May 3, 2024, that it believes to have regained compliance with Nasdaq's Minimum Stockholders’ Equity Requirement of $2.5 million. This follows capital raising activities completed in November 2023 and February 2024, including an amendment to a common stock purchase warrant. The company is currently awaiting confirmation from Nasdaq regarding its compliance status. Vivos Therapeutics anticipates that Nasdaq will monitor its ongoing compliance and acknowledges the need to raise additional equity capital to maintain this compliance. The company also recognizes the risk of being unable to raise sufficient capital, which could lead to delisting from Nasdaq and have a material adverse effect on its stock price, trading ability, capital raising capabilities, and reputation.
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the symbol VVOS, has reported on May 3, 2024, that it believes to have regained compliance with Nasdaq's Minimum Stockholders’ Equity Requirement of $2.5 million. This follows capital raising activities completed in November 2023 and February 2024, including an amendment to a common stock purchase warrant. The company is currently awaiting confirmation from Nasdaq regarding its compliance status. Vivos Therapeutics anticipates that Nasdaq will monitor its ongoing compliance and acknowledges the need to raise additional equity capital to maintain this compliance. The company also recognizes the risk of being unable to raise sufficient capital, which could lead to delisting from Nasdaq and have a material adverse effect on its stock price, trading ability, capital raising capabilities, and reputation.
Vivos Therapeutics, Inc. 是一家在纳斯达克股票市场上市的特拉华州注册公司，股票代码为VVOS。该公司于2024年5月3日报告称，它认为已恢复遵守纳斯达克250万美元的最低股东权益要求。在此之前，筹资活动于2023年11月和2024年2月完成，包括对普通股购买权证的修订。该公司目前正在等待纳斯达克对其合规状况的确认。Vivos Therapeutics预计，纳斯达克将监督其持续的合规情况，并承认需要筹集额外的股权资本以维持这种合规性。该公司还认识到无法筹集足够资金的风险，这可能导致从纳斯达克退市，并对其股价、交易能力、筹资能力和声誉产生重大不利影响。
Vivos Therapeutics, Inc. 是一家在纳斯达克股票市场上市的特拉华州注册公司，股票代码为VVOS。该公司于2024年5月3日报告称，它认为已恢复遵守纳斯达克250万美元的最低股东权益要求。在此之前，筹资活动于2023年11月和2024年2月完成，包括对普通股购买权证的修订。该公司目前正在等待纳斯达克对其合规状况的确认。Vivos Therapeutics预计，纳斯达克将监督其持续的合规情况，并承认需要筹集额外的股权资本以维持这种合规性。该公司还认识到无法筹集足够资金的风险，这可能导致从纳斯达克退市，并对其股价、交易能力、筹资能力和声誉产生重大不利影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息